Unlike monoclonal antibodies, bispecific antibodies bind to 2 different antigens simultaneously,[1][1] directing T cells toward cancer cells to exert a cytotoxic killing effect.[1][1] Bispecific ...

Panelists discuss how to identify, monitor, and manage delayed toxicities following ciltacabtagene autoleucel (cilta-cel) chimeric antigen receptor (CAR) T therapy, including prolonged cytopenias, ...

The findings, published in the Lancet Oncology, highlight the importance of developing strategies to better manage acute toxicities to help improve long-term outcomes and quality of life for patients.

A recent meta-analysis shows that acute toxicities following radiation therapy signal a greater risk for later complications in patients with prostate cancer.

Impaired renal function and cisplatin-based regimens as risk factors for neoadjuvant chemotherapy-induced acute kidney injury in muscle-invasive bladder cancer: A multicenter retrospective study. This ...